FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4299580293> ?p ?o ?g. }

• W4299580293 endingPage "498" @default.
• W4299580293 startingPage "492" @default.
• W4299580293 abstract "No AccessJournal of UrologyClinical Urology: Original Article1 Feb 1997Evolution and Clinical Significance of the T Cell Proliferative and Cytokine Response Directed Against the Fibronectin Binding Antigen 85 Complex of Bacillus Calmette-Guerin During Intravesical Treatment of Superficial Bladder Cancer Alexandre R. Zlotta, Annie Drowart, Jean-Paul Van Vooren, Michel de Cock, Michel Pirson, Kamiel Palfliet, Fabienne Jurion, Albert Vanonckelen, Jacques Simon, Claude C. Schulman, and Kris Huygen Alexandre R. ZlottaAlexandre R. Zlotta More articles by this author , Annie DrowartAnnie Drowart More articles by this author , Jean-Paul Van VoorenJean-Paul Van Vooren More articles by this author , Michel de CockMichel de Cock More articles by this author , Michel PirsonMichel Pirson More articles by this author , Kamiel PalflietKamiel Palfliet More articles by this author , Fabienne JurionFabienne Jurion More articles by this author , Albert VanonckelenAlbert Vanonckelen More articles by this author , Jacques SimonJacques Simon More articles by this author , Claude C. SchulmanClaude C. Schulman More articles by this author , and Kris HuygenKris Huygen More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)65185-1AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The antitumorigenic effect of intravesical bacillus Calmette-Guerin (BCG) in superficial bladder cancer was reported to be initiated by the attachment of BCG to the bladder wall via fibronectin. The antigen 85 complex secreted in BCG culture filtrate binds specifically to fibronectin and is a powerful T cell stimulus. Therefore, we investigated the evolution and clinical significance of the cellular proliferative response and cytokine production during intravesical BCG therapy against this purified antigen 85 complex. Materials and Methods: Evolution of the lymphoproliferation, interleukin-2 and interferon-gamma production of peripheral blood lymphocytes against tuberculin (purified protein derivative), purified antigen 85, BCG culture filtrate, whole BCG bacilli and pokeweed mitogen was tested before and after 6 weekly intravesical BCG instillations in 29 patients with superficial bladder cancer at intermediate or high risk for recurrence. Results: A major increase in the lymphoproliferative response against purified protein derivative, antigen 85, BCG culture filtrate, whole BCG and pokeweed mitogen was observed in 69.0, 65.5, 79.3, 48.3 and 65.3% of the patients, respectively, analyzed after BCG therapy. Reactivity returned to baseline values at 6 months of followup. Of the patients who received a second BCG course because of tumor recurrence 66% had a novel increase in lymphoproliferation against antigen 85. An increase in the production of interleukin-2 and interferon-gamma by peripheral lymphocytes against antigen 85 was noted in 42.1 and 50% of the treated patients, respectively, after a single BCG course. During a mean followup of 23.11 months 48.5% of the patients remained tumor-free. No correlation could be found between the immunological response against any of the BCG antigens and the clinical evolution of the response. Conclusions: Intravesical BCG instillations induce a transient (less than 6 months) peripheral immune activation against several purified BCG antigens and among them the fibronectin binding antigen 85 complex. Reactivation is observed in most cases after additional BCG courses. The absence of long lasting immune activation after a single 6-week course of BCG could be related to the increased clinical efficacy observed with BCG maintenance instillations. References 1 : Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. N. Amer.1992; 19: 573. Google Scholar 2 : Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J. Urol.1994; 152: 367. Link, Google Scholar 3 : T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol.1993; 150: 1018. Link, Google Scholar 4 : The induction of bacillus-Calmette-Guerin activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immun. Immunother.1995; 40: 103. Google Scholar 5 : Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J. Urol.1990; 144: 59. Abstract, Google Scholar 6 : Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol.1990; 144: 53. Link, Google Scholar 7 : Efficacy of a BCG glycan preparation, PS1, in two animal bladder cancer models. J. Urol., part 21995; 153: 487A. abstract 1036. Google Scholar 8 : Fibronectin mediated bacille Calmette-Guerin attachment to murine bladder mucosa: requirement for expression of an antitumor response. J. Clin. Invest.1990; 85: 62. Google Scholar 9 : The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol. Rev.1992; 56: 648. Google Scholar 10 : The genes coding for the antigen 85-complex of M. tuberculosis and M. bovis BCG are members of a gene family: cloning, sequence determination and genomic organization of the gene coding for the antigen 85-C of M. tuberculosis. Infect. Immun.1991; 59: 3205. Google Scholar 11 : The major secreted antigen complex (Ag 85) from M. bovis bacille Calmette-Guerin is associated with protective T-cells in leprosy: a follow-up study of 45 household contacts. J. Infect. Dis.1993; 167: 1160. Google Scholar 12 : Specific lymphoproliferation, gamma interferon production and serum immunoglobulin G directed against a purified 32 kDa mycobacterial protein antigen (P32) in patients with active tuberculosis. Scand. J. Immunol.1988; 27: 187. Google Scholar 13 : Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol.1992; 147: 596. Link, Google Scholar 14 : Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette-Guerin therapy. J. Urol.1993; 149: 268. Link, Google Scholar 15 : T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect. Immun.1994; 62: 3679. Google Scholar 16 : Spleen cell cytokine secretion in M. bovis BCG-infected mice. Infect. Immun.1992; 60: 2880. Google Scholar 17 : Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and anti-microbial activity. J. Exp. Med.1983; 158: 670. Google Scholar 18 : The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J. Urol.1991; 145: 1078. Link, Google Scholar 19 : Immunity to mycobacteria. Curr. Opin. Immunol.1993; 5: 497. Google Scholar 20 : Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J. Urol.1985; 134: 48. Link, Google Scholar 21 : Morphological aspects of the interaction of bacillus Calmette-Guerin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity? Urol. Res.1992; 20: 219. Google Scholar 22 : Limited clonal heterogeneity of antigen-specific T cells localizing in the pleural space during mycobacterial infection. Infect. Immun.1991; 59: 503. Google Scholar 23 : BCG in perspective: advances in the treatment of superficial bladder cancer. Eur. Urol.1995; 27: 2. Google Scholar 24 : Effects of local BCG therapy in patients with bladder carcinoma on phenotypes and function of mononuclear cells. In: Immunotherapy of Urological Tumours, International Society of Urology Reports. Edited by . New York: Churchill Livingstone1990: 83. Google Scholar 25 : Peripheral blood lymphocyte response in patients with superficial transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guerin-a useful marker of response? Brit. J. Urol.1993; 71: 179. Google Scholar 26 : Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J. Urol.1996; 155: 477. Link, Google Scholar 27 : Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer. J. Urol.1996; 155: 888. Google Scholar 28 : Biochemistry of bladder cancer invasion and metastasis. Clinical implications. Urol. Clin. N. Amer.1992; 19: 621. Google Scholar 29 : p53 status and the efficacy of cancer therapy in vivo. Science1994; 266: 807. Google Scholar Department of Urology and Chest Department, Erasme Hospital, University Clinics of Brussels and Department of Virology, Pasteur Institute of Brussels, Brussels, Belgium.© 1997 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited By (2018) EDITORIAL COMMENTJournal of Urology, VOL. 166, NO. 4, (1305-1305), Online publication date: 1-Oct-2001.ELSÄSSER-BEILE U, GUTZEIT O, BAUER S, KATZENWADEL A, SCHULTZE-SEEMANN W and WETTERAUER U (2018) SYSTEMIC AND LOCAL IMMUNOMODULATORY EFFECTS OF INTRAVESICAL BCG THERAPY IN PATIENTS WITH SUPERFICIAL URINARY BLADDER CARCINOMASJournal of Urology, VOL. 163, NO. 1, (296-299), Online publication date: 1-Jan-2000.ZLOTTA A, NOEL J, FAYT I, DROWART A, VAN VOOREN J, HUYGEN K, SIMON J and SCHULMAN C (2018) CORRELATION AND PROGNOSTIC SIGNIFICANCE OF p53, p21WAF1/CIP1 AND Ki-67 EXPRESSION IN PATIENTS WITH SUPERFICIAL BLADDER TUMORS TREATED WITH BACILLUS CALMETTE-GUERIN INTRAVESICAL THERAPYJournal of Urology, VOL. 161, NO. 3, (792-798), Online publication date: 1-Mar-1999.ZLOTTA A, DROWART A, VAN VOOREN J, SHEKARSARAI H, DE COCK M, PIRSON M, PALFLIET K, JURION F, SIMON J, SCHULMAN C and HUYGEN K (2018) SUPERFICIAL BLADDER TUMORS AND INCREASED REACTIVITY AGAINST MYCOBACTERIAL ANTIGENS BEFORE BACILLUS CALMETTE-GUERIN THERAPYJournal of Urology, VOL. 159, NO. 6, (1885-1891), Online publication date: 1-Jun-1998. Volume 157Issue 2February 1997Page: 492-498 Advertisement Copyright & Permissions© 1997 by American Urological Association, Inc.MetricsAuthor Information Alexandre R. Zlotta More articles by this author Annie Drowart More articles by this author Jean-Paul Van Vooren More articles by this author Michel de Cock More articles by this author Michel Pirson More articles by this author Kamiel Palfliet More articles by this author Fabienne Jurion More articles by this author Albert Vanonckelen More articles by this author Jacques Simon More articles by this author Claude C. Schulman More articles by this author Kris Huygen More articles by this author Expand All Advertisement PDF DownloadLoading ..." @default.
• W4299580293 created "2022-10-02" @default.
• W4299580293 creator A5012397578 @default.
• W4299580293 creator A5017814466 @default.
• W4299580293 creator A5019295957 @default.
• W4299580293 creator A5028851875 @default.
• W4299580293 creator A5031111261 @default.
• W4299580293 creator A5045879589 @default.
• W4299580293 creator A5047486184 @default.
• W4299580293 creator A5069564756 @default.
• W4299580293 creator A5072702419 @default.
• W4299580293 creator A5079091216 @default.
• W4299580293 creator A5082788593 @default.
• W4299580293 date "1997-02-01" @default.
• W4299580293 modified "2023-10-13" @default.
• W4299580293 title "Evolution and Clinical Significance of the T Cell Proliferative and Cytokine Response Directed Against the Fibronectin Binding Antigen 85 Complex of Bacillus Calmette-Guerin During Intravesical Treatment of Superficial Bladder Cancer" @default.
• W4299580293 cites W1423791052 @default.
• W4299580293 cites W171038488 @default.
• W4299580293 cites W1801265254 @default.
• W4299580293 cites W1953993731 @default.
• W4299580293 cites W1993559923 @default.
• W4299580293 cites W1994396826 @default.
• W4299580293 cites W2005088674 @default.
• W4299580293 cites W2016971744 @default.
• W4299580293 cites W2041063967 @default.
• W4299580293 cites W2081166109 @default.
• W4299580293 cites W2081894694 @default.
• W4299580293 cites W2134990166 @default.
• W4299580293 cites W2142328554 @default.
• W4299580293 cites W2157707418 @default.
• W4299580293 cites W2160040629 @default.
• W4299580293 cites W2407337242 @default.
• W4299580293 cites W2408301264 @default.
• W4299580293 cites W2408781918 @default.
• W4299580293 cites W2411180784 @default.
• W4299580293 cites W2412492782 @default.
• W4299580293 cites W2413740587 @default.
• W4299580293 cites W2414572565 @default.
• W4299580293 cites W2417786234 @default.
• W4299580293 cites W2460892140 @default.
• W4299580293 cites W4229738288 @default.
• W4299580293 cites W4301266192 @default.
• W4299580293 doi "https://doi.org/10.1016/s0022-5347(01)65185-1" @default.
• W4299580293 hasPublicationYear "1997" @default.
• W4299580293 type Work @default.
• W4299580293 citedByCount "30" @default.
• W4299580293 countsByYear W42995802932015 @default.
• W4299580293 countsByYear W42995802932019 @default.
• W4299580293 countsByYear W42995802932020 @default.
• W4299580293 countsByYear W42995802932021 @default.
• W4299580293 countsByYear W42995802932022 @default.
• W4299580293 countsByYear W42995802932023 @default.
• W4299580293 crossrefType "journal-article" @default.
• W4299580293 hasAuthorship W4299580293A5012397578 @default.
• W4299580293 hasAuthorship W4299580293A5017814466 @default.
• W4299580293 hasAuthorship W4299580293A5019295957 @default.
• W4299580293 hasAuthorship W4299580293A5028851875 @default.
• W4299580293 hasAuthorship W4299580293A5031111261 @default.
• W4299580293 hasAuthorship W4299580293A5045879589 @default.
• W4299580293 hasAuthorship W4299580293A5047486184 @default.
• W4299580293 hasAuthorship W4299580293A5069564756 @default.
• W4299580293 hasAuthorship W4299580293A5072702419 @default.
• W4299580293 hasAuthorship W4299580293A5079091216 @default.
• W4299580293 hasAuthorship W4299580293A5082788593 @default.
• W4299580293 hasConcept C121608353 @default.
• W4299580293 hasConcept C126322002 @default.
• W4299580293 hasConcept C147483822 @default.
• W4299580293 hasConcept C1491633281 @default.
• W4299580293 hasConcept C203014093 @default.
• W4299580293 hasConcept C2777701055 @default.
• W4299580293 hasConcept C2778690821 @default.
• W4299580293 hasConcept C2780352672 @default.
• W4299580293 hasConcept C502942594 @default.
• W4299580293 hasConcept C55493867 @default.
• W4299580293 hasConcept C71924100 @default.
• W4299580293 hasConcept C86492073 @default.
• W4299580293 hasConcept C86803240 @default.
• W4299580293 hasConcept C8891405 @default.
• W4299580293 hasConceptScore W4299580293C121608353 @default.
• W4299580293 hasConceptScore W4299580293C126322002 @default.
• W4299580293 hasConceptScore W4299580293C147483822 @default.
• W4299580293 hasConceptScore W4299580293C1491633281 @default.
• W4299580293 hasConceptScore W4299580293C203014093 @default.
• W4299580293 hasConceptScore W4299580293C2777701055 @default.
• W4299580293 hasConceptScore W4299580293C2778690821 @default.
• W4299580293 hasConceptScore W4299580293C2780352672 @default.
• W4299580293 hasConceptScore W4299580293C502942594 @default.
• W4299580293 hasConceptScore W4299580293C55493867 @default.
• W4299580293 hasConceptScore W4299580293C71924100 @default.
• W4299580293 hasConceptScore W4299580293C86492073 @default.
• W4299580293 hasConceptScore W4299580293C86803240 @default.
• W4299580293 hasConceptScore W4299580293C8891405 @default.
• W4299580293 hasIssue "2" @default.
• W4299580293 hasLocation W42995802931 @default.
• W4299580293 hasOpenAccess W4299580293 @default.
• W4299580293 hasPrimaryLocation W42995802931 @default.
• W4299580293 hasRelatedWork W181678093 @default.
• W4299580293 hasRelatedWork W1996150995 @default.

• next